Altimmune to Participate at Two Upcoming Investor Conferences
31 mai 2023 07h30 HE
|
Altimmune, Inc
GAITHERSBURG, Md., May 31, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will...
Altimmune Announces First Quarter 2023 Financial Results and Provides a Business Update
11 mai 2023 07h00 HE
|
Altimmune, Inc
Initiation of the IMPACT Phase 2b trial of pemvidutide in non-alcoholic steatohepatitis (NASH) expected mid-2023 Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 ...
Altimmune to Participate at Two Upcoming Investor Conferences
08 mai 2023 07h30 HE
|
Altimmune, Inc
GAITHERSBURG, Md., May 08, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will...
Altimmune to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023
04 mai 2023 07h30 HE
|
Altimmune, Inc
GAITHERSBURG, Md., May 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2023 financial...
Altimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell™, an Immunotherapeutic for Chronic Hepatitis B
11 avr. 2023 07h30 HE
|
Altimmune, Inc
GAITHERSBURG, Md., April 11, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company (the Company), today announced that it has completed enrollment in its...
Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors
27 mars 2023 16h05 HE
|
Altimmune, Inc
GAITHERSBURG, Md., March 27, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Catherine Angell Sohn, Pharm.D. to...
Altimmune Announces Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM Phase 2 Obesity Trial and 12-Week Phase 1b Type 2 Diabetes Safety Trial
21 mars 2023 07h00 HE
|
Altimmune, Inc
MOMENTUM Phase 2 Obesity Trial (Week 24 Interim Analysis of 160 Subjects) Mean weight loss of 10.7% (placebo-adjusted 9.7%) at 2.4 mg dose at Week 24Mean weight loss of 11.9% (placebo-adjusted 11.1%)...
Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
28 févr. 2023 07h00 HE
|
Altimmune, Inc
Interim 24-week readout from MOMENTUM Phase 2 obesity trial expected March 2023 Initiation of Phase 2b non-alcoholic steatohepatitis (NASH) trial expected mid-2023 Webcast to be held today, February...
Altimmune to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023
21 févr. 2023 07h30 HE
|
Altimmune, Inc
GAITHERSBURG, Md., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year...
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023
04 janv. 2023 07h30 HE
|
Altimmune, Inc
GAITHERSBURG, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Chairman and Co-Founder,...